Instanyl (Fentanyl Nasal Spray)
Opioid analgesic for the management of breakthrough cancer pain in opioid-tolerant adults
Instanyl is a prescription nasal spray containing fentanyl, a potent synthetic opioid analgesic approximately 50–100 times more powerful than morphine. It is used exclusively for the treatment of breakthrough cancer pain in adult patients who are already receiving and tolerant to ongoing opioid therapy. Due to its rapid absorption through the nasal mucosa, Instanyl provides fast-acting relief within minutes — a critical feature for managing the sudden, intense pain flares that characterize breakthrough cancer pain.
Quick Facts
Key Takeaways
- Instanyl contains fentanyl, a potent Schedule II opioid, and is intended only for breakthrough cancer pain in patients already on maintenance opioid therapy.
- Pain relief typically begins within 10 minutes of intranasal administration, with peak effect at approximately 12–15 minutes.
- The correct dose must be individually titrated under medical supervision — do not assume equivalence with other fentanyl products.
- Serious risks include life-threatening respiratory depression, addiction, abuse, and fatal overdose from accidental exposure, especially in children.
- Must be stored securely in its child-resistant container — accidental exposure in children is a medical emergency.
What Is Instanyl and What Is It Used For?
Quick Answer: Instanyl is a fentanyl nasal spray prescribed exclusively for the treatment of breakthrough cancer pain in adults who are already receiving and tolerant to opioid therapy for their underlying chronic cancer pain.
Instanyl belongs to a class of medications known as opioid analgesics. Its active ingredient, fentanyl, is a synthetic phenylpiperidine derivative that acts on mu-opioid receptors in the brain and spinal cord to produce powerful pain relief. Fentanyl is considered one of the most potent opioid analgesics available in clinical practice, with an estimated potency 50 to 100 times greater than morphine on a milligram-per-milligram basis.
The medication is specifically designed for breakthrough cancer pain (BTcP), which refers to transient flares of pain that occur in patients who otherwise have adequately controlled background pain with around-the-clock opioid therapy. Breakthrough pain episodes are a common and distressing complication of cancer, affecting an estimated 40–80% of cancer patients receiving opioid maintenance therapy, according to European Society for Medical Oncology (ESMO) guidelines. These episodes typically arise suddenly, reach peak intensity within minutes, and last for an average of 30–60 minutes.
The intranasal route of administration offers several clinical advantages over oral opioid formulations for breakthrough pain. Because fentanyl is rapidly absorbed through the highly vascular nasal mucosa, it bypasses first-pass hepatic metabolism and achieves therapeutic plasma levels much faster than oral preparations. Clinical studies have demonstrated that Instanyl provides clinically meaningful pain relief as early as 10 minutes after administration, with peak plasma concentrations occurring at approximately 12–15 minutes. This pharmacokinetic profile closely matches the temporal pattern of breakthrough cancer pain episodes.
Instanyl is available in three dose strengths — 50, 100, and 200 micrograms per actuation — allowing for individualized dose titration. The correct dose for any given patient must be determined through a structured titration process supervised by a physician experienced in opioid therapy for cancer patients. The dose of Instanyl is independent of the patient's background opioid dose and cannot be predicted based on the maintenance opioid regimen.
Instanyl must NEVER be used for any type of pain other than breakthrough cancer pain. It is not indicated for acute pain, postoperative pain, headaches, migraines, dental pain, or any non-cancer pain condition. Use in opioid-non-tolerant patients can cause fatal respiratory depression.
What Should You Know Before Taking Instanyl?
Quick Answer: Instanyl must only be used by opioid-tolerant cancer patients under specialist supervision. Multiple serious contraindications and precautions apply, including risks during pregnancy and concurrent use with other CNS depressants.
Contraindications
Instanyl is strictly contraindicated in the following situations:
- Opioid-non-tolerant patients: Patients who are not receiving regular opioid therapy must never use Instanyl. Opioid tolerance is defined as taking at least 60 mg of oral morphine daily, at least 25 micrograms/hour of transdermal fentanyl, at least 30 mg of oral oxycodone daily, at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid for at least one week.
- Hypersensitivity: Known allergy to fentanyl or any of the excipients in the formulation.
- Severe respiratory depression: Patients with significant respiratory compromise or severe obstructive lung disease.
- Concurrent MAO inhibitor use: Instanyl must not be used within 14 days of MAO inhibitor therapy due to the risk of severe, unpredictable potentiation of opioid effects.
- Severe nasal conditions: Active nasal mucosal damage, recurrent epistaxis, or nasal radiation therapy that could alter absorption.
Warnings and Precautions
Before and during treatment with Instanyl, several important safety considerations must be carefully evaluated by the prescribing physician and understood by the patient:
- Respiratory depression: This is the most serious risk associated with Instanyl. Fentanyl can cause dose-dependent respiratory depression that may be fatal. The risk is highest during initiation of therapy, dose escalation, or concomitant use with other CNS depressants. Naloxone (an opioid antagonist) should be available as a rescue medication.
- Addiction, abuse, and misuse: As a Schedule II controlled substance, Instanyl carries a risk of opioid addiction, abuse, and misuse, even at recommended doses. Patients with a history of substance use disorders may require enhanced monitoring.
- Accidental exposure: Accidental exposure to Instanyl, particularly in children, can result in fatal overdose. The nasal spray must be kept in its child-resistant container at all times when not in use.
- CNS depression: Fentanyl may impair mental and physical abilities. Patients should not drive, operate heavy machinery, or perform potentially dangerous activities until they know how Instanyl affects them.
- Head injuries and raised intracranial pressure: Fentanyl may obscure the clinical course of head injuries and should be used with extreme caution in these patients.
- Hepatic or renal impairment: Fentanyl is primarily metabolized in the liver; dose adjustments and careful monitoring may be necessary in patients with hepatic or renal dysfunction.
- Concomitant nasal medications: Nasal decongestants such as oxymetazoline may reduce fentanyl absorption. If nasal decongestants are required, they should be used at a different time than Instanyl if possible.
Pregnancy and Breastfeeding
Instanyl should not be used during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the fetus. Prolonged use of opioids during pregnancy can cause neonatal opioid withdrawal syndrome (NOWS), which may be life-threatening if not recognized and treated. Symptoms of NOWS include irritability, excessive crying, tremors, feeding difficulties, diarrhea, and in severe cases, seizures.
Fentanyl is excreted into breast milk and can cause sedation and respiratory depression in nursing infants. Breastfeeding is generally not recommended during treatment with Instanyl. If breastfeeding is considered, the decision should be made in close consultation with the treating physician, weighing the benefits of breastfeeding for the child against the therapeutic needs of the mother.
Labour and delivery: Fentanyl is not recommended for use during labour and delivery, including caesarean section, as fentanyl crosses the placenta and may cause respiratory depression in the newborn. If a neonate is exposed to fentanyl during delivery, a specific opioid antagonist (naloxone) should be readily available.
How Does Instanyl Interact with Other Drugs?
Quick Answer: Instanyl can interact dangerously with CNS depressants (benzodiazepines, alcohol, other opioids), CYP3A4 inhibitors, serotonergic medications, and MAO inhibitors. Concurrent use of these agents increases the risk of respiratory depression, sedation, serotonin syndrome, or other life-threatening effects.
Fentanyl is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver and intestinal mucosa. Drugs that inhibit or induce this enzyme can significantly alter fentanyl plasma levels and clinical effects. Additionally, the pharmacodynamic interactions of fentanyl with other CNS-active substances can profoundly affect patient safety.
Major Interactions
| Drug / Drug Class | Interaction Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Benzodiazepines (diazepam, midazolam, alprazolam) | Pharmacodynamic | Profound sedation, respiratory depression, coma, death | Avoid concurrent use when possible. If necessary, use lowest effective doses and monitor closely. |
| CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, itraconazole) | Pharmacokinetic | Increased fentanyl plasma levels, prolonged sedation and respiratory depression | Use with caution. Monitor for signs of opioid toxicity. Dose reduction may be needed. |
| MAO inhibitors (phenelzine, tranylcypromine, selegiline) | Pharmacodynamic | Severe, unpredictable potentiation of opioid effects; potentially fatal | Contraindicated. Do not use Instanyl within 14 days of MAO inhibitor use. |
| Serotonergic drugs (SSRIs, SNRIs, triptans, tramadol) | Pharmacodynamic | Serotonin syndrome (agitation, hyperthermia, tachycardia, rigidity) | Monitor for serotonin syndrome symptoms. Consider alternative medications if possible. |
| Other opioids, alcohol | Pharmacodynamic | Additive CNS depression, respiratory depression | Use with extreme caution. Monitor respiratory function closely. |
Minor Interactions
Several additional drug interactions deserve clinical attention, although they are generally less immediately dangerous than the major interactions listed above:
- CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): These can decrease fentanyl plasma levels, potentially reducing analgesic efficacy. Patients switching to or from CYP3A4 inducers may need dose adjustments.
- Muscle relaxants (baclofen, tizanidine, cyclobenzaprine): May enhance the CNS-depressant effects of fentanyl, increasing the risk of drowsiness and respiratory depression.
- Anticholinergic drugs: Concurrent use may increase the risk of urinary retention and severe constipation, which may lead to paralytic ileus.
- Mixed opioid agonists/antagonists (buprenorphine, nalbuphine, pentazocine): May reduce the analgesic effect of fentanyl or precipitate withdrawal symptoms in opioid-dependent patients.
- Nasal vasoconstrictors (oxymetazoline): May decrease the rate of fentanyl absorption through the nasal mucosa, potentially delaying the onset of pain relief.
Always inform your healthcare provider and pharmacist about all medications you are taking, including prescription drugs, over-the-counter medications, herbal products, and dietary supplements. Grapefruit juice is a moderate CYP3A4 inhibitor and should be avoided or consumed with caution during Instanyl treatment.
What Is the Correct Dosage of Instanyl?
Quick Answer: The correct dose of Instanyl must be individually determined through a structured titration process starting at the lowest available dose (50 mcg). The effective dose cannot be predicted from the patient's maintenance opioid regimen and must be established under medical supervision.
Adults
Instanyl dosing follows a mandatory titration protocol to identify the minimum effective dose for each patient. The titration process should be supervised by a physician experienced in opioid therapy for cancer patients.
Titration Phase
Begin with the lowest dose strength: 50 micrograms (one spray in one nostril). If adequate pain relief is not achieved within 10 minutes, a second spray of 50 mcg may be administered in the other nostril. If the 50 mcg dose proves insufficient over several breakthrough pain episodes, the dose may be escalated to 100 mcg, and subsequently to 200 mcg, following the same assessment protocol.
Maintenance Phase
Once the effective dose has been established, patients should use one spray per breakthrough pain episode. A second dose may be taken if pain persists after 10 minutes, but patients must wait at least 4 hours before treating another breakthrough pain episode with Instanyl. The maximum recommended frequency is 4 episodes per day. If more than 4 breakthrough pain episodes occur daily, the background opioid therapy should be reassessed.
| Titration Step | Dose per Spray | Initial Dose | Supplementary Dose (after 10 min) |
|---|---|---|---|
| Step 1 (starting dose) | 50 mcg | 1 spray in one nostril | 1 spray in other nostril (50 mcg) |
| Step 2 | 100 mcg | 1 spray in one nostril | 1 spray in other nostril (100 mcg) |
| Step 3 (maximum) | 200 mcg | 1 spray in one nostril | 1 spray in other nostril (200 mcg) |
Children and Adolescents
Instanyl is not recommended for use in children and adolescents under the age of 18 years. The safety and efficacy of intranasal fentanyl for breakthrough cancer pain have not been established in the paediatric population. There are no adequate data from clinical trials to support dosing recommendations in this age group.
Elderly Patients
Elderly patients (aged 65 years and older) may be more sensitive to the effects of fentanyl due to age-related changes in pharmacokinetics, including reduced hepatic metabolism and renal clearance, as well as altered body composition. These changes can lead to higher plasma fentanyl concentrations and prolonged drug effects. Dose titration in elderly patients should proceed with particular caution, and the starting dose should always be 50 micrograms. Close monitoring for signs of respiratory depression, excessive sedation, and confusion is essential throughout treatment.
Missed Dose
Instanyl is used on an as-needed basis for breakthrough cancer pain and is not taken on a fixed schedule. Therefore, the concept of a missed dose does not apply to this medication. Patients should only use Instanyl when a breakthrough pain episode occurs and should not take additional doses to compensate for untreated episodes.
Overdose
A fentanyl overdose is a life-threatening medical emergency. Symptoms of overdose include severe respiratory depression (very slow, shallow, or absent breathing), extreme drowsiness or unresponsiveness, pinpoint pupils (miosis), cold and clammy skin, cyanosis (blue discoloration of lips and fingernails), loss of consciousness, and cardiac arrest.
Immediate actions:
- Call emergency services immediately.
- Administer naloxone (Narcan) if available — naloxone is a specific opioid antagonist that rapidly reverses respiratory depression.
- Ensure the patient's airway is open and provide rescue breathing if needed.
- Because fentanyl's duration of action may exceed that of naloxone, repeated doses of naloxone may be necessary.
- Stay with the patient until emergency medical help arrives.
What Are the Side Effects of Instanyl?
Quick Answer: The most common side effects of Instanyl include nausea, vertigo, drowsiness, and headache. Serious but less common side effects include respiratory depression, which can be life-threatening. Side effects are generally consistent with those expected from opioid medications.
Like all opioid medications, Instanyl can cause side effects, although not everyone experiences them. The side effect profile of intranasal fentanyl is generally consistent with the known pharmacological effects of opioids. Most common side effects are dose-dependent and may diminish with continued use as some degree of tolerance develops. The following frequency classification is based on clinical trial data and post-marketing surveillance, using the standard Medical Dictionary for Regulatory Activities (MedDRA) frequency convention.
Very Common (affects more than 1 in 10 people)
Frequency: >10%
- Nausea
- Vertigo (dizziness)
Common (affects 1 to 10 in 100 people)
Frequency: 1–10%
- Drowsiness (somnolence)
- Headache
- Vomiting
- Constipation
- Nasal discomfort, throat irritation
- Rhinorrhoea (runny nose)
- Hyperhidrosis (excessive sweating)
- Fatigue and malaise
- Flushing and hot flush
- Pruritus (itching)
Uncommon (affects 1 to 10 in 1,000 people)
Frequency: 0.1–1%
- Respiratory depression
- Hypotension (low blood pressure)
- Nasal ulceration or epistaxis (nosebleeds)
- Confusion and disorientation
- Hallucinations
- Dysgeusia (altered taste)
- Urinary retention
- Muscle twitching or myoclonus
- Skin rash
Rare (affects fewer than 1 in 1,000 people)
Frequency: <0.1%
- Severe anaphylactic/anaphylactoid reactions
- Seizures
- Loss of consciousness
- Nasal septal perforation (with prolonged use)
- Adrenal insufficiency
- Androgen deficiency (with chronic use)
- Serotonin syndrome (with concurrent serotonergic drugs)
Contact emergency services immediately if you or a caregiver notice any of the following: very slow, shallow, or irregular breathing; extreme drowsiness with difficulty waking; blue or purple discoloration of lips, fingers, or toes; cold and clammy skin; loss of consciousness. These may be signs of a life-threatening opioid overdose.
Long-term use of opioids, including fentanyl, may lead to physical dependence and tolerance. Physical dependence is an expected physiological response to chronic opioid therapy and should not be confused with addiction. However, abrupt discontinuation of Instanyl after prolonged use can cause withdrawal symptoms, including restlessness, anxiety, muscle aches, insomnia, sweating, runny nose, nausea, vomiting, diarrhoea, and abdominal cramps. Any dose reduction or discontinuation should be carried out gradually under medical supervision.
Opioid-induced hyperalgesia (OIH) is a paradoxical increase in pain sensitivity that may occur with chronic opioid use. If a patient reports increasing pain despite stable or escalating opioid doses, OIH should be considered as a possible explanation, and the treating physician should evaluate the need to adjust the overall pain management strategy.
How Should You Store Instanyl?
Quick Answer: Store Instanyl below 30°C in the upright position. Do not freeze. Always keep the nasal spray in its child-resistant container when not in use. Dispose of unused medication according to local regulations or return it to a pharmacy.
Proper storage of Instanyl is critically important, both to maintain the medication's effectiveness and to prevent potentially fatal accidental exposure, particularly in children. The following storage and handling guidelines should be strictly observed:
- Temperature: Store below 30°C (86°F). Do not freeze the nasal spray. If the solution has been frozen, do not use it — discard and obtain a new unit.
- Position: Store the nasal spray device in the upright position to ensure proper functioning of the spray mechanism.
- Child-resistant container: Always return the nasal spray to its child-resistant outer container immediately after each use. This is a critical safety measure — even a single accidental dose of Instanyl in a child can cause fatal respiratory depression.
- Shelf life: Do not use Instanyl after the expiry date printed on the packaging. Once opened, the nasal spray should be used within the timeframe specified on the product label, typically within the shelf life of the overall product.
- Disposal: Do not dispose of Instanyl in household waste or flush it down the toilet. Return unused or expired nasal sprays to a pharmacy for safe disposal. Many communities offer drug take-back programmes for controlled substances.
Fentanyl exposure in children is a medical emergency. Even residual amounts of fentanyl in a used nasal spray device can be lethal to a small child. Always store Instanyl in a secure location that is completely inaccessible to children. If accidental exposure is suspected, call emergency services immediately and administer naloxone if available.
What Does Instanyl Contain?
Quick Answer: The active ingredient in Instanyl is fentanyl (as fentanyl citrate). The solution also contains sodium dihydrogen phosphate dihydrate, disodium phosphate dihydrate, and purified water.
Each dose (actuation) of Instanyl delivers a precisely measured amount of fentanyl as the citrate salt. The nasal spray solution is a clear, colourless solution provided in a multi-dose glass bottle fitted with a metered-dose spray pump.
Active Ingredient
- Fentanyl (as fentanyl citrate) — available in 50, 100, or 200 micrograms per actuation, depending on the product strength.
Excipients (Inactive Ingredients)
- Sodium dihydrogen phosphate dihydrate (buffering agent)
- Disodium phosphate dihydrate (buffering agent)
- Purified water (vehicle)
The formulation is designed to maintain a pH close to the physiological pH of the nasal mucosa (approximately pH 6.0–6.5), which optimizes both patient comfort and fentanyl absorption. The solution does not contain preservatives, and the multi-dose spray device is designed to prevent microbial contamination during use.
Instanyl contains no lactose, gluten, sucrose, or common allergenic food-derived excipients. Patients with known allergies should review the full excipient list with their pharmacist or prescribing physician.
Frequently Asked Questions About Instanyl
Instanyl (fentanyl nasal spray) is a prescription opioid medication used specifically for the management of breakthrough cancer pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain refers to sudden, intense pain flares that occur despite ongoing around-the-clock opioid treatment. Instanyl is NOT indicated for any other type of pain, including acute pain, postoperative pain, headaches, or migraine.
Instanyl provides rapid pain relief due to its intranasal delivery route. Fentanyl is absorbed quickly through the nasal mucosa, with onset of pain relief typically occurring within 10 minutes of administration. Peak plasma concentrations are reached in approximately 12–15 minutes. This rapid onset makes Instanyl particularly well-suited for breakthrough cancer pain episodes, which are characteristically sudden and intense.
Instanyl (fentanyl nasal spray) and fentanyl transdermal patches serve different purposes in cancer pain management. Fentanyl patches provide continuous, slow-release pain relief over 48–72 hours and are used for around-the-clock background pain. Instanyl delivers a rapid dose of fentanyl through the nose for immediate relief of breakthrough pain episodes. They are often used together: the patch for baseline pain and the nasal spray for sudden pain flares.
No. Instanyl must only be used by adults who are already opioid-tolerant, meaning they are regularly taking opioid medications for chronic cancer pain. Specifically, patients must be receiving at least 60 mg of oral morphine daily, 25 micrograms/hour of transdermal fentanyl, or an equivalent dose of another opioid for at least one week. Using Instanyl without established opioid tolerance can cause life-threatening respiratory depression.
The most dangerous side effect of Instanyl is respiratory depression (slowed or stopped breathing), which can be life-threatening. Other serious risks include addiction, abuse, and misuse, even at recommended doses. CNS depression, severe hypotension, and serotonin syndrome (when combined with serotonergic drugs) are also potential serious adverse effects. Accidental exposure, particularly in children, can result in fatal overdose. Naloxone should be available as a rescue medication.
Instanyl must be stored securely out of reach and sight of children due to the extreme danger of accidental exposure. Store below 30°C in the upright position. Do not freeze. Keep the nasal spray in its child-resistant container when not in use. Unused or expired Instanyl should be disposed of according to local regulations or returned to a pharmacy. Never flush opioid medications down the toilet or dispose of them in household waste.
References
- European Medicines Agency (EMA). Instanyl — Summary of Product Characteristics. Last updated 2025. Available at: EMA Product Information.
- World Health Organization (WHO). Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: WHO; 2018.
- Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Annals of Oncology. 2024;35(11):919–942.
- Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncology. 2023;13(2):e58–e68.
- Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41(3):273–281.
- Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine. European Journal of Pain. 2009;13(4):331–338.
- Mercadante S, Portenoy RK. Breakthrough cancer pain: twenty-five years of study. Pain. 2016;157(12):2657–2663.
- British National Formulary (BNF). Fentanyl — Intranasal Preparations. NICE Evidence Services. 2025.
Editorial Team
Medical Review
This article has been reviewed by the iMedic Medical Review Board, comprising board-certified physicians specializing in pain medicine, palliative care, oncology, and clinical pharmacology. All medical claims are verified against current international guidelines (WHO, EMA, ESMO, EAPC) and peer-reviewed literature.
Editorial Standards
iMedic follows a rigorous editorial process based on the GRADE evidence framework. All content undergoes medical fact-checking, clinical accuracy review, and accessibility testing. We maintain complete editorial independence with no pharmaceutical industry funding or influence.
Evidence Level: 1A — Based on systematic reviews and meta-analyses of randomized controlled trials, international clinical guidelines (WHO, EMA, ESMO), and regulatory-approved prescribing information.
Conflict of Interest: None declared. iMedic receives no funding from pharmaceutical companies.